Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~

~ Grant Funds from NIDA Accelerating Clinical Development Program ~

SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has fully enrolled Part 2 of the critical three-part PF614-MPAR-102 clinical study to study the effect of food on the MPAR technology.

PF614-MPAR has earned the FDA's prestigious Breakthrough Therapy designation and is uniquely engineered using Ensysce's proprietary TAAP (Trypsin-Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance) technologies. These platforms enable PF614-MPAR to maintain therapeutic efficacy while delivering built-in overdose protection when doses exceed prescribed amounts, whether accidentally or intentionally.

A three-year grant from the National Institute on Drug Abuse (NIDA), with second year funding recently announced¹, continues to support this program through May 2027. This support will accelerate the clinical development of PF614-MPAR and could help launch a new era in pain relief with overdose protection.

"This is more than a study milestone - it's a turning point in pain medicine," said Dr. Lynn Kirkpatrick, CEO of Ensysce. "We are moving closer to delivering a new class of opioid that not only relieves pain but also shields patients from the danger of overdose. We believe PF614-MPAR has the potential to redefine opioid safety for millions of patients."

¹The research is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number UO1DA059791.

About Ensysce Biosciences

Ensysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP^TM) and Multi-Pill Abuse Resistance (MPAR) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.